Is ACRV diluting shareholders?

Read three numbers together: shares outstanding over time (42.9M as of 2026-08-07), warrants that can convert into new shares (0 reported), and how much cash runway remains (~16.956066912746405 months). A company short on cash with live registrations is structurally likely to issue shares.

Where do these numbers come from?

SEC EDGAR only: the XBRL company-facts API for shares, warrants and cash, and filing metadata for registrations and pricings. Every figure shows its source form, and nothing here is estimated by us beyond the arithmetic stated next to it.

Why might a warrant tranche be missing from the table?

The tranche table is built from the dimensions the company tagged in its own 10-Q or 10-K XBRL. A tranche the filer chose not to dimension does not appear, and its absence proves nothing: the exhibits remain the ground truth. Everything shown carries the filing it came from.

Dilution profile // every instrument, one screen, from SEC filings

Acrivon Therapeutics, Inc. (ACRV)

CIK 1781174 · all EDGAR filings →

Overall dilution risk

HIGHworst of 4 computed signals (offering ability)

= the worst band among the computed sub-ratings, no hidden weighting

Offering ability

HIGHS-3 on file 2024-04-17

= is there a registration (S-1/S-3 family) on file without a later withdrawal

no structured fee data on the live registrations, so this is a yes/no, not a size

Overhead supply

LOWwarrants = 0% of O/S

= warrant shares outstanding divided by current shares outstanding (bands: 20% / 50%)

warrants only; converts, ATMs and equity lines are not in free structured data, so the true overhead is AT LEAST this

Historical dilution

MEDIUM+94% O/S in 3y

= share count now vs 3 years ago (bands: 30% / 100%); a reverse split pushes this negative

Cash need

MEDIUM~17 months of runway

= cash vs trailing operating burn (bands: 6mo / 24mo; positive operating CF = low)

Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.

Shares outstanding over time

Latest: 42.9M shares as of Aug 7, 2026 (10-Q).

Cash runway

Funded — but tight

~17 months of cash · watch

Full breakdown: cash runway tool · source filing →

Warrants

Tranche	Warrants	Exercise price	Term	Notes
Pre Funded Warrants	7.1M	$0.001	—	—

Tranches exactly as the company dimensioned them in its 10-Q filed May 13, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.

Warrants outstanding: 0 underlying shares, as reported Mar 31, 2026 (10-Q).

Rough fully diluted estimate: 42.9M = 42.9M O/S + 0 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.

Convertible notes

No convertible-note facts tagged in the 10-Q filed Aug 12, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.

Fully diluted build-up

Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.

Shares outstanding	42.9M	Aug 7, 2026
+ Pre Funded Warrants (if exercised)	7.1M	Apr 8, 2024
Fully diluted estimate	49.9M	+16.5% vs O/S

Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.

Registrations and offerings

S-3Apr 17, 2024no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →

S-3Dec 1, 2023no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →

Last 12 months: 0 executed · 0 registered.

EFFECTIVEApr 29, 2024SEC declared a registration effective — selling can beginEFFECT →

REGISTEREDApr 17, 2024S-3 registration — capacity to sell shares, not a sale yetS-3 →

EXECUTEDApr 9, 2024Unregistered share sale disclosed (8-K item 3.02)8-K →

EFFECTIVEDec 15, 2023SEC declared a registration effective — selling can beginEFFECT →

REGISTEREDDec 1, 2023S-3 registration — capacity to sell shares, not a sale yetS-3 →

EXECUTEDNov 17, 2022Unregistered share sale disclosed (8-K item 3.02)8-K →

EXECUTEDNov 16, 2022Final prospectus — offering priced (typical for IPOs and marketed share deals)424B4 →

MARKETINGNov 14, 2022Free-writing prospectus — offering being marketedFWP →

REGISTEREDNov 14, 2022S-1MEF registration — capacity to sell shares, not a sale yetS-1MEF →

EFFECTIVENov 9, 2022SEC declared a registration effective — selling can beginEFFECT →

REGISTEREDNov 8, 2022S-1/A registration — capacity to sell shares, not a sale yetS-1/A →

REGISTEREDNov 3, 2022S-1/A registration — capacity to sell shares, not a sale yetS-1/A →

Full history and shelf status: offering checker · S-3 shelf checker

Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.

Keep going: float checker · offering calendar · short-squeeze screener · full ACRV workspace